Farms.com Home   News

Candidate Proteins Now Being Tested for Inclusion in Lawsonia Intracellularis Vaccines

Researchers with VID0-InterVac have started analysing proteins that offer potential for the creation of a protein based Lawsonia intracellularis vaccine. Lawsonia intracellularis, a bacteria found in about 90 percent of the world's swine herds, causes Ileitis, a swelling of the intestine in pigs.

Researchers with VIDO-InterVac are using various methods, including bioinformatics, or computer analysis, to identify proteins that can be used to create a vaccine.

Dr. Heather Wilson a Research Scientist with the Vaccine and Infectious Disease Organization, says scientists are working to identify proteins that will trigger a B-Cell response or a T-Cell response.

Clip-Dr. Heather Wilson-VID0-InterVac:

We are studying Lawsonia intracellularis vaccine development because we want to make a protein-based vaccine. Alternative forms of vaccines could be using an inactivated bacteria or a killed bacteria. We wanted to use a very simplified version where you just have a few proteins derived from the bacteria and we grow them up and include them in the vaccine and we get a very targeted immune response.

The trick is trying to figure out which of the proteins out of all the bacterial proteins which ones do we want to include in the vaccines for it to be effective. We are testing some vaccine antigens right now that trigger a good B-Cell response, so produce antibodies.

That’s kind of half of the equation and right now we're just in the process of trying to identify T-Cell antigens using the bioinfromatics approach. That's fairly early days through the bioinfromatics but we're hoping within the year we can be testing our vaccine candidates.

Source : Farmscape

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.